دورية أكاديمية
Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
| العنوان: | Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. |
|---|---|
| المؤلفون: | Vu DM; Center for Disease Control and Vaccination, National Hospital for Tropical Diseases, Hanoi, Vietnam., Vu DTB; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam., Do TTT; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam., Olmsted AE; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam., Dao BH; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam., Thai TT; Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam., Nguyen CL; Global Health, Association of Public Health Laboratories, Hanoi, Vietnam., Le NTT; Global Health, Association of Public Health Laboratories, Hanoi, Vietnam., Le TA; Center of Training and Research Management, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam., Bui HTT; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam., Pham TN; National Hospital for Tropical Diseases, Hanoi, Vietnam., Moore MR; Division of Global Health Protection, US Centers for Disease Control and Prevention, Hanoi, Vietnam. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Oct 03; Vol. 75 (Suppl 2), pp. S174-S181. |
| نوع المنشور: | Journal Article; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | COVID-19*/epidemiology , COVID-19*/prevention & control , Viral Vaccines*, Antibodies, Neutralizing ; Antibodies, Viral ; Asian People ; ChAdOx1 nCoV-19 ; Health Personnel ; Humans ; Immunoglobulin G ; Prospective Studies ; SARS-CoV-2 ; Seroepidemiologic Studies ; Vaccination ; Vietnam/epidemiology |
| مستخلص: | Background: Before the SARS-CoV-2 Delta variant arrived in Vietnam, case rates suggested seroprevalence of SARS-CoV-2 was low. Beginning in March 2021, we assessed different dosing schedules and adverse events following immunization (AEFIs) for ChAdOx1 nCoV-19 vaccine among healthcare workers (HCWs). Methods: We performed a prospective cohort study to estimate the prevalence of IgG antibodies to SARS-CoV-2 before and after ChAdOx1 nCoV-19 vaccination. We conducted antibody testing among HCWs in February 2021 (baseline), before the second dose (June-July 2021), and 1 and 3 months after the second dose. We detected antibodies to SARS-CoV-2 using Tetracore® FlexImmArray™, and surrogate neutralizing antibodies using GenScript cPass™. Neither assay can distinguish natural from vaccine-induced antibodies. We assessed AEFIs through interview post-dose 1 and 1 month post-dose 2. Results: Before vaccination, 1/617 participants (0.16%) had antibodies to SARS-CoV-2. Of these 617, 405 were vaccinated with ChAdOx1 nCoV-19 with 4-8- (60%), 9-12- (27%), or ≥13-week (13%) intervals between the 2 doses. Three months following series completion, 99% and 97% of vaccinated participants had ≥1 sample with detectable antibodies and surrogate neutralizing antibodies against SARS-CoV-2, respectively. We observed no significant differences among those with different dosing intervals at last follow-up. All participants reported PCR testing for SARS-CoV-2 during the study; 2 (0.5%) were laboratory-confirmed. AEFIs were more frequent post-dose 1 (81%) vs post-dose 2 (21%). Conclusions: In this population, regardless of dosing interval, ChAdOx1 nCoV-19 induced antibodies within 3 months of the second dose. These findings may offer flexibility to policymakers when balancing programmatic considerations with vaccine effectiveness. Competing Interests: Potential conflicts of interest . The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.) |
| معلومات مُعتمدة: | United States CC CDC HHS |
| فهرسة مساهمة: | Keywords: SARS-CoV-2; seroprevalence; vaccination |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (Immunoglobulin G) 0 (Viral Vaccines) B5S3K2V0G8 (ChAdOx1 nCoV-19) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20220620 Date Completed: 20221005 Latest Revision: 20230117 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9278177 |
| DOI: | 10.1093/cid/ciac493 |
| PMID: | 35723271 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciac493 |